GILZ protein levels in sepsis: Impact of comorbidities in a cross-sectional ICU study
Bali Medical Journal · 16.05.2026 · 15 (2) · 191-196
DOI: 10.15562/bmj.v15i2.5890 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Bali Medical Journal, online erschienen am 16.05.2026. Verfasst von Mutia Lailani und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Sepsis
Abstract (Originalsprache)
Introduction
Sepsis is characterized by a dysregulated host response to infection, involving a complex interplay between pro-inflammatory and anti-inflammatory pathways. Glucocorticoid-induced leucine zipper (GILZ) is a pivotal anti-inflammatory protein that mediates glucocorticoid effects by inhibiting major pro-inflammatory transcription factors. While GILZ shows promise as a therapeutic target, the impact of clinical comorbidities on its expression in sepsis patients remains poorly understood. This study aimed to describe GILZ protein concentrations in sepsis patients and to evaluate whether the presence of single or multiple comorbidities influences these levels in an intensive care setting.
Methods
This cross-sectional study prospectively enrolled 36 adult patients with sepsis admitted to the Intensive Care Unit (ICU) of Dr. M. Djamil General Hospital, Padang, Indonesia. Clinical characteristics and the presence of comorbidities (chronic kidney disease, acute kidney injury, type 2 diabetes mellitus, and hypertension) were recorded. Plasma GILZ protein concentrations were measured using an enzyme-linked immunosorbent assay (ELISA). Comparisons between patients without comorbidities and those with specific or multiple conditions were performed using the Mann-Whitney U test.
Results
The study population comprised 18 males and 18 females, with a mean age of 59.61±14.85 years. No statistically significant differences in GILZ protein concentrations were found between patients without comorbidities (0.112±0.035 ng/mL) and those with multiple comorbidities (0.109±0.029 ng/mL; p = 0.944), chronic kidney disease (0.119±0.036 ng/mL; p = 0.920), acute kidney injury (0.095±0.014 ng/mL; p = 0.193), type 2 diabetes mellitus (0.087±0.008 ng/mL; p = 0.114), or hypertension (0.097±0.017 ng/mL; p = 0.430).
Conclusion
GILZ protein concentrations in sepsis patients are not significantly altered by underlying comorbidities. This suggests that the induction of GILZ is a robust physiological response to acute septic insult, independent of a patient’s pre-existing chronic health status, thereby supporting its potential as a consistent therapeutic target in a heterogeneous ICU population.
Zitieren
APA
Lailani, M., & Aliska, G. (2026). GILZ protein levels in sepsis: Impact of comorbidities in a cross-sectional ICU study. Bali Medical Journal, 15(2), 191-196. https://doi.org/10.15562/bmj.v15i2.5890
Vancouver
Lailani M, Aliska G. GILZ protein levels in sepsis: Impact of comorbidities in a cross-sectional ICU study. Bali Medical Journal. 2026;15(2):191-196. doi:10.15562/bmj.v15i2.5890
BibTeX
@article{Lailani2026,
author = {Lailani, Mutia and Aliska, Gestina},
title = {GILZ protein levels in sepsis: Impact of comorbidities in a cross-sectional ICU study},
journal = {Bali Medical Journal},
year = {2026},
volume = {15},
number = {2},
pages = {191--196},
doi = {10.15562/bmj.v15i2.5890}
}
EUVIMED